Myeloma ASH 22

Ajai Chari, MDVideo Insights | March 3, 2023
Ajai Chari, MD, of Mount Sinai School of Medicine, discusses results from the MonumenTAL-1 phase I/II study of talquetamab.
Leah SherwoodMeeting News | December 27, 2022
Patients with multiple myeloma receiving BCMA-targeted therapies are at high risk of infectious complications.
Leah SherwoodMyeloma | February 8, 2024
Gary Schiller, MD, of the University of California, Los Angeles, discusses the STOMP study.
Advertisement
Chadi Nabhan, MD, MBA, FACPMyeloma | January 10, 2023
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, discusses novel therapies in myeloma, MRD data, and more.
Chadi Nabhan, MD, MBA, FACPVideo Insights | January 10, 2023
Thomas Martin, MD, discusses advances in frontline treatments for multiple myeloma, the need for novel agents, and more.
Cecilia BrownMyeloma | December 14, 2022
Patients with heavily pretreated multiple myeloma who received bispecific CAR T-cells had an OS rate of 83.9%.
Advertisement
Cecilia BrownVideo Insights | January 11, 2023
Sandy Wong, MD, discusses results from a phase I first-in-human study of alnuctamab in patients with relapsed/refractory MM.
Cecilia BrownMyeloma | December 12, 2022
The phase I UNIVERSAL trial showed allogeneic CAR-T therapy led to “significant and durable responses” in patients with ...
Leah LawrenceMyeloma | December 10, 2022
Use of drugs with alternative modes of action may be needed to overcome persistent MRD positivity in myeloma.
Leah LawrenceMyeloma | December 10, 2022
Selinexor combinations had moderate efficacy in real-world patients with relapsed or refractory multiple myeloma.
Kerri FitzgeraldMyeloma | December 10, 2022
A new study presented at the 2022 ASH Annual Meeting identified causes of the increased myeloma risk in Black Americans.
Cecilia BrownMyeloma | December 10, 2022
BCMA-directed CAR-T led to a CR in 75% in relapsed/refractory multiple myeloma who received allogeneic HSCT.
Cecilia BrownMyeloma | December 10, 2022
A new study suggests many interventional phase III clinical trials in myeloma didn't clearly define high-risk disease.
Leah LawrenceMeeting News | December 8, 2022
More genetic information is needed to investigate the link between racial ancestry and outcomes in multiple myeloma.
Advertisement
Advertisement
Editorial Board